+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tenapanor in adults with Chronic Idiopathic Constipation CIC. This study is a 26-week, multi-center, randomized, double-blind, placebo-controlled trial followed by a 4-week treatment-free safety follow-up period. It aims to compare three different doses of tenapanor with a placebo taken twice daily to assess their impact on constipation symptoms. The study includes a 2-week screening period to confirm eligibility, followed by a 26-week randomized treatment period where patients receive either 5 mg, 25 mg, or 50 mg of tenapanor twice daily, or a matching placebo. Patients record their constipation symptoms daily in an electronic diary. After the treatment period, there is a 4-week safety follow-up without treatment to monitor any adverse effects. Participants will have regular visits every 2 to 6 weeks for safety checks including medical assessments, vital signs, ECG, and lab tests. Their symptom diaries will be reviewed throughout the study. The main outcome measured is the durable complete spontaneous bowel movements response at 12 weeks. Secondary outcomes include changes in bowel movement frequency, stool consistency, and straining. The total study duration is approximately 32 weeks including all phases.

Age: 18Years - 80YearsAll GendersPhase 3
109 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of subcutaneous anifrolumab injections compared to placebo in adults with moderate to severe Idiopathic Inflammatory Myopathies IIM, including polymyositis PM and dermatomyositis DM. This Phase III, multicenter, randomized, placebo-controlled, and double-blind study adds anifrolumab or placebo to participants standard of care treatment to assess overall disease activity. Participants receive either anifrolumab or a matched placebo by subcutaneous injection once weekly for 52 weeks while continuing their standard treatments. After this period, all participants have the option to receive open-label anifrolumab weekly for an additional 52 weeks. This design allows researchers to compare the effects of anifrolumab against placebo and then observe longer-term effects when all receive anifrolumab. Throughout the study, participants undergo regular assessments including the Total Improvement Score TIS at 52 weeks as the main outcome. Additional evaluations include muscle strength testing, corticosteroid dosage monitoring, skin disease activity, and itch severity up to 52 weeks. Safety and disease activity improvements for both PM and DM participants are closely monitored. The study lasts up to approximately two years, including both blinded and open-label treatment phases.

Age: 18Years - 75YearsAll GendersPhase 3
237 locations
E

Actively Recruiting

This trial evaluates the efficacy, safety, and tolerability of switching from glucagon-like peptide-1 receptor agonists GLP-1RA to maridebart cafraglutide in adults with obesity or overweight. It aims to assess how maridebart cafraglutide affects body weight and other safety measures in this population. The study is a Phase 3, open-label, randomized trial sponsored by Amgen. Participants are randomly assigned to one of two dosing schedules of maridebart cafraglutide, which is administered via subcutaneous injection. The treatment period involves receiving one of these dosing regimens to compare their effects. The study focuses on switching from prior weekly GLP-1RA treatment to maridebart cafraglutide and monitors participants throughout the treatment. During the trial, participants will have their body weight measured at baseline and at Week 68 to determine the percentage change. Additional assessments include plasma concentration of maridebart cafraglutide and monitoring for treatment-emergent adverse events up to 84 weeks. Participants are expected to maintain stable body weight and gastrointestinal tolerability before and during the trial, with contraception required for females. Overall, the study duration extends through the treatment period and safety follow-up.

Age: 18Years - 99YearsAll GendersPhase 3
54 locations
G

Actively Recruiting

This research aims to gather real-world data on the outcomes of Boston Scientific neurostimulation systems used for pain management in everyday clinical practice. It focuses on evaluating the long-term effectiveness, economic value, and technical performance of these commercially approved neurostimulation devices when used according to their instructions. Participants will undergo a trial period with a Boston Scientific neurostimulation system for pain. Those who experience positive results from the trial may then receive a permanent implant of the neurostimulation system. The therapy will be personalized based on the investigators judgment and routine site care, following the studys inclusion and exclusion criteria. During the study, participants will be monitored as they receive neurostimulation therapy in real-world settings. Researchers will collect information on treatment outcomes and device performance over time. The study spans from 2012 to 2035, allowing for long-term observation of participants using these neurostimulation systems for pain relief.

Age: 18Years +All Genders
118 locations
E

Actively Recruiting

Researchers are studying the safety and tolerability of switching from semaglutide to a new combined treatment called CagriSema in adults with type 2 diabetes. This phase 3 clinical trial evaluates three different dosing schedules of CagriSema in people who have been taking semaglutide once weekly. The goal is to understand how well participants tolerate this switch and monitor any side effects during the treatment period. Participants who have been treated with once-weekly semaglutide will switch to one of three regimens involving once-weekly doses of CagriSema. The first group will switch directly to dose 1 of CagriSema, the second group will start with dose 2 then switch to dose 1, and the third group will begin with dose 3, then move to dose 2, and finally dose 1. All doses are given by subcutaneous injection once weekly. The study lasts approximately six months for each participant. During the trial, participants will be monitored for treatment-emergent adverse events from the start of treatment through week 16 and up to week 22. Assessments include checking for episodes of low blood sugar confirmed by glucose measurements and gastrointestinal side effects that may cause participants to stop treatment. Participants will have regular visits to track safety and tolerability while receiving the study drug. The overall study duration for participants is about six months.

Age: 18Years +All GendersPhase 3
40 locations
E

Actively Recruiting

Researchers are evaluating the real-world effects and safety of dupilumab in people with chronic obstructive pulmonary disease COPD. The study aims to describe the characteristics of participants newly starting dupilumab for COPD and compare them with COPD patients not treated with dupilumab. The research will also look at whether dupilumab reduces moderate or severe COPD flare-ups, improves lung function, enhances quality of life, and monitor safety in these participants. The study will enroll 350 COPD participants newly prescribed dupilumab over about 12 months at around 20 US sites, alongside a control group of 700 COPD participants not receiving dupilumab from an external registry. Data collected will include chest images and home spirometry measurements. Participants will receive usual care as decided by themselves and their healthcare providers. Participants will be followed and monitored for approximately 2 years, during which chest images, lung function tests, and quality of life assessments will be gathered. Researchers will evaluate participant characteristics at the end of the study and track COPD exacerbations, lung function changes, and safety events. The study involves no assigned treatments, and participants continue their regular medical care throughout the observation period.

Age: 40Years +All Genders
7 locations